The DOI matches its Crossref record; 117 of the 118 references it cites were found in a registry or an index.
Primary and Secondary Prevention of Cardiovascular Disease
Open accessAbstract
Background This guideline focuses on long-term administration of antithrombotic drugs designed for primary and secondary prevention of cardiovascular disease, including two new antiplatelet therapies. Methods The methods of this guideline follow those described in Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in this supplement. Results We present 23 recommendations for pertinent clinical questions. For primary prevention of cardiovascular disease, we suggest low-dose aspirin (75-100 mg/d) in patients aged > 50 years over no aspirin therapy (Grade 2B). For patients with established coronary artery disease, defined as patients 1-year post-acute coronary syndrome, with prior revascularization, coronary stenoses > 50% by coronary angiogram, and/or evidence for cardiac ischemia on diagnostic testing, we recommend long-term low-dose aspirin or clopidogrel (75 mg/d) (Grade 1A). For patients with acute coronary syndromes who undergo percutaneous coronary intervention (PCI) with stent placement, we recommend for the first year dual antiplatelet therapy with low-dose aspirin in combination with ticagrelor 90 mg bid, clopidogrel 75 mg/d, or prasugrel 10 mg/d over single antiplatelet therapy (Grade 1B). For patients undergoing elective PCI with stent placement, we recommend aspirin (75-325 mg/d) and clopidogrel for a minimum duration of 1 month (bare-metal stents) or 3 to 6 months (drug-eluting stents) (Grade 1A). We suggest continuing low-dose aspirin plus clopidogrel for 12 months for all stents (Grade 2C). Thereafter, we recommend single antiplatelet therapy over continuation of dual antiplatelet therapy (Grade 1B). Conclusions Recommendations continue to favor single antiplatelet therapy for patients with established coronary artery disease. For patients with acute coronary syndromes or undergoing elective PCI with stent placement, dual antiplatelet therapy for up to 1 year is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence supports use of either ticagrelor or clopidogrel if no percutaneous coronary intervention was performed and clopidogrel, ticagrelor, or prasugrel if a percutaneous coronary intervention was performed (199).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [199]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Evidence supports use of either ticagrelor or clopidogrel if no percutaneous coronary intervention was performed and clopidogrel, ticagrelor, or prasugrel if a percutaneous coronary intervention was performed (187).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [187]
In the citing paper
“Evidence supports use of either ticagrelor or clopidogrel if no percutaneous coronary intervention was performed and clopidogrel, ticagrelor , or prasugrel if a percutaneous coronary intervention was performed (162).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [162]
In the citing paper
“Co-prescription of OAC with antiplatelet therapy, in particular triple therapy, 1501 increases the absolute risk of major haemorrhage.445,517,518”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [517]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm
Lip, G. Y. H., Wrigley, B., & Pisters, R. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003333 · Cited by 32
RetractedPrediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Self-citationHansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Flagged first, then by citations
1 of the 118 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Wilson, 1998, Prediction of coronary artery disease using risk factor categories, Circulation, 97, 1837, 10.1161/01.CIR.97.18.1837 · DOI · Paper page
Cited by
Sorted by citations
Items 301–400 of 475
Use of Alternative Antiplatelet Agents for Clopidogrel Hypersensitivity
Ather, A., & Beavers, C. J. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161116666180730100806 · Cited by 4
Plazak, M. E., Mouradjian, M. T., Watson, K., Reed, B. N., Noel, Z. R., Devabhakthuni, S., & Gale, S. E. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1642108 · Cited by 4
Novel oral anticoagulants in intracardiac thrombosis resolution: a case series
Al‐Sadawi, M., Francois, J. C., Ortega, R. R., Capric, V., & Budzikowski, A. S. (2020) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytaa181 · Cited by 4
Drozd, A., Szczuko, M., Bohatyrewicz, A., Jurewicz, A., & Kotlęga, D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092652 · Cited by 4
Çelik, O. (2018) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2018.47587 · Cited by 4
Ratcovich, H., Holmvang, L., Johansson, P. I., & Dridi, N. (2015) · Platelets · doi:10.3109/09537104.2015.1029899 · Cited by 4
Usharani, P. (2013) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2013/6884.3584 · Cited by 4
From clinical questions to trustworthy answers
Vandvik, P. O., Bretthauer, M., & Kongerud, I. C. (2013) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.13.0650 · Cited by 4
Self-citationUse and Misuse of Aspirin in Primary Cardiovascular Prevention
COCCHERI, S. (2017) · Clinical Medicine Insights Cardiology · doi:10.1177/1179546817702149 · Cited by 4
Перепеч, Н. Б., & Трегубов, А. В. (2018) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2018-14-2-235-243 · Cited by 4
Clinical Epidemiology and Evidence-Based Health Care
Schünemann, H. J., & Guyatt, G. H. (2013) · Springer eBooks · doi:10.1007/978-0-387-09834-0_30 · Cited by 4
Self-citationUnmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban
Eikelboom, J. W., & Connolly, S. J. (2015) · Cardiology Research · doi:10.14740/cr413w · Cited by 2
Statins and Aspirin: Do They Really Work in Women?
Desai, H. G., Hollingsworth, P. W., & Chugh, A. R. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0111-x · Cited by 3
Knight, S., Klaskala, W. I., Woller, S. C., Horne, B. D., Bunch, T. J., Le, V. T., Mills, R. M., & Muhlestein, J. B. (2015) · Cardiology Research and Practice · doi:10.1155/2015/270508 · Cited by 3
Ticagrelor for acute coronary syndromes
Bansilal, S., Bonaca, M. P., & Sabatine, M. S. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2013.839205 · Cited by 3
Clinical trials in long-term antiplatelet therapies
Goel, R., & Baber, U. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000640 · Cited by 3
Clinical use of low-dose aspirin for elders and sensitive subjects
Zhang, Y., Fang, X., & Chen, G. (2019) · World Journal of Clinical Cases · doi:10.12998/wjcc.v7.i20.3168 · Cited by 3
Patrono, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-47462-5_83 · Cited by 3
Im, C., Park, Y. S., Min, S.-H., Kang, S. H., Lee, S. J., Lee, E., Yoo, M., Hwang, D., Ahn, S.-H., Suh, Y., et al. (2023) · Annals of Surgical Treatment and Research · doi:10.4174/astr.2023.104.2.80 · Cited by 3
Effect of Low-Dose Aspirin on the Elderly
Darraj, A. (2024) · Cureus · doi:10.7759/cureus.54658 · Cited by 3
van Peet, P. G., Gussekloo, J., den Elzen, W. P. J., Blom, J. W., de Waal, M. W. M., & de Ruijter, W. (2015) · Scandinavian Journal of Primary Health Care · doi:10.3109/02813432.2015.1117281 · Cited by 3
Patrick, J., Johnson, A., Dillaha, L., & Pennell, A. T. (2016) · Future Cardiology · doi:10.2217/fca-2016-0042 · Cited by 3
Станиславовна, К. Е., Zemlyanskaya, O. A., Dobrovolsky, A. B., & Панченко, Е. П. (2019) · Russian Cardiology Bulletin · doi:10.17116/cardiobulletin20191401123 · Cited by 3
Review of the top 5 cardiology studies of 2017-18
Barry, A. R., Babadagli, H. E., Chen, J. W., May, T. A., McMillan, C. L., Omar, M. A., Pollmann, D. M., Zhou, J. S., & Ackman, M. L. (2019) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/1715163519882464 · Cited by 3
Khalili, M., Lepeytre, F., Guertin, J. R., Goupil, R., Troyanov, S., Bouchard, J., & Madore, F. (2020) · CMAJ Open · doi:10.9778/cmajo.20190105 · Cited by 3
O’Malley, D. M., Blair, C. K., Greenbaum, A., Wiggins, C. L., Rajput, A., Chiu, V. K., & Kinney, A. Y. (2022) · Journal of Community Genetics · doi:10.1007/s12687-021-00574-9 · Cited by 4
Antithrombotics in heart failure
Miličić, D., Samardžić, J., & Petričević, M. (2014) · Croatian Medical Journal · doi:10.3325/cmj.2014.55.621 · Cited by 3
Aspirin in the prevention of cardiovascular disease and cancer
Paek, Y., & Yoon, J. L. (2014) · Journal of Korean Medical Association · doi:10.5124/jkma.2014.57.4.348 · Cited by 3
Towards a global brief on aspirin
Algra, A. M. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60772-2 · Cited by 3
The risks and benefits of prophylactic aspirin in vascular disease and cancer
Elwood, P. C., Mustafa, M., Almonte, M., & Morgan, G. (2012) · Clinical Investigation · doi:10.4155/cli.12.124 · Cited by 3
DeAnda, A., & Cayne, N. S. (2013) · Hospital Practice · doi:10.3810/hp.2013.04.1024 · Cited by 3
Leipziger, D. (2017) · Routledge eBooks · doi:10.4324/9781351278881-40 · Cited by 3
PHARMACOGENETICS OF ANTITHROMBOTIC DRUGS: STATUS UPDATE ON THE PROBLEM
Станиславовна, К. Е. (2018) · Aterotromboz = Atherothrombosis · doi:10.21518/2307-1109-2018-2-115-129 · Cited by 3
Antithrombotic Therapy for Stroke Patients with Cardiovascular Disease
Gusdon, A. M., Farrokh, S., & Grotta, J. C. (2021) · Seminars in Neurology · doi:10.1055/s-0041-1726331 · Cited by 4
Venous and Arterial Thrombosis Is There a Link?
Prandoni, P. (2015) · Advances in experimental medicine and biology · doi:10.1007/13780_2015_13 · Cited by 3
The Caprini Risk Score for Early Prediction of Mortality in Patients With Acute Coronary Syndrome
Li, W., Wang, Y., Li, D., Jia, Y., Li, F., Chen, T., Liu, Y., Zeng, Z., Wan, Z., Zeng, R., et al. (2022) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000000949 · Cited by 3
Climbing a long hill: pelvic floor surgery and the need for geriatric urogynecology
Betschart, C., & Rizk, D. E. E. (2014) · International Urogynecology Journal · doi:10.1007/s00192-013-2302-9 · Cited by 3
Kopjar, T., Biočina, B., & Petričević, M. (2012) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2012.06.059 · Cited by 3
Ruiz‐García, A., Pallarés‐Carratalá, V., Serrano-Cumplido, A., Escobar-Cervantes, C., Barquilla-García, A., Divisón, J. A., Turégano-Yedro, M., Prieto-Díaz, M. Á., Cinza‐Sanjurjo, S., Alonso-Moreno, F. J., et al. (2022) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2021.12.002 · Cited by 2
Rodríguez‐Martín, S., García‐Lledó, A., Gil, M., Barreira‐Hernández, D., Rodríguez, A., & de Abajo, F. J. (2020) · Medicina Clínica · doi:10.1016/j.medcli.2019.10.012 · Cited by 2
Oxman, A., Chalmers, I., & Dahlgren, A. (2022) · Journal of the Royal Society of Medicine · doi:10.1177/01410768221140786 · Cited by 2
Stylianou, V. V., Tsampasian, V., Pavlou, M., Georgiou, P., Patestos, D., Kapetis, L., Vassiliou, V. S., Eftychiou, C., Tsielepis, M., & Bazoukis, G. (2023) · Clinical Case Reports · doi:10.1002/ccr3.7300 · Cited by 2
Wada, S., Iwanaga, Y., Nakai, M., Miyamoto, Y., & Noguchi, T. (2024) · Heart and Vessels · doi:10.1007/s00380-024-02394-6 · Cited by 2
Wada, S., Sakuraba, M., Nakai, M., Suzuki, T., Miyamoto, Y., Noguchi, T., & Iwanaga, Y. (2024) · Internal Medicine · doi:10.2169/internalmedicine.3566-24 · Cited by 2
Chaverri‐Fernández, J. M., León, C. R., Leu, A. Y., & Zavaleta‐Monestel, E. (2020) · Acta Médica Costarricense · doi:10.51481/amc.v57i1.864 · Cited by 2
Aspirin dosage for the prevention of graft occlusion in people undergoing coronary surgery
Alahdab, F., Jazayerli, M. L., Alhalabi, O., Hasan, S. M., Mallak, M., Alkhouli, M. A., Haydour, Q., & Murad, M. H. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012113 · Cited by 3
RetractedPrimary prevention of cardiovascular diseases in diabetes mellitus: 2020 strategy
Novikov, V. I., & Novikov, K. Y. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-4-42-49 · Cited by 2
Alahdab, F., Yafi, R. Z., Chaar, A., Alrstom, A., Alzuabi, M. A., Alhalabi, O., Hasan, S. M., Mallak, M., Jazayerli, M., Haydour, Q., et al. (2020) · Avicenna Journal of Medicine · doi:10.4103/ajm.ajm_17_20 · Cited by 3
Jackson, M. B. (2014) · Springer eBooks · doi:10.1007/978-3-319-09366-6_7 · Cited by 2
Intertrochanteric Fracture: How to Improve the Surgical Outcomes?
Oh, H. K. (2015) · The Journal of the Korean Orthopaedic Association · doi:10.4055/jkoa.2015.50.3.192 · Cited by 2
Tan, H., Mahadeva, S., Menon, J., Ng, W. K., Abidin, I. Z., Chan, F. K. L., & Goh, K. (2012) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12000 · Cited by 2
Cardio-embolic stroke following remote blunt chest trauma
Arora, S., Atreya, A. R., Penumetsa, S. C., & Hiser, W. (2013) · Journal of Cardiovascular Disease Research · doi:10.1016/j.jcdr.2013.02.007 · Cited by 2
Volpe, M., Abrignani, M. G., Borghi, C., COCCHERI, S., Gresele, P., Patti, G., Trimarco, B., & Caterina, R. D. (2014) · Giornale italiano di cardiologia · doi:10.1714/1596.17424 · Cited by 8
The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes
Reddy, P., & Giugliano, R. P. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414525505 · Cited by 2
Aspirin use for primary prevention in elderly patients
Terrosu, P. (2016) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2015.728 · Cited by 2
Thorat, M. A. (2016) · BMC Medicine · doi:10.1186/s12916-016-0648-9 · Cited by 2
Pharmacogenomics of Clopidogrel
Giusti, B., Saracini, C., Galora, S., & Marcucci, R. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386882-4.00025-6 · Cited by 2
Oral antiplatelet agents for the management of acute coronary syndromes
Gesheff, T. B., & Barbour, C. (2017) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12438 · Cited by 2
Perioperative Cardioprotective Strategies in Noncardiac Surgery
Hert, S. G. D. (2017) · Springer eBooks · doi:10.1007/978-3-319-47609-4_41 · Cited by 3
Thornton, J. D., Agarwal, P., & Sambamoorthi, U. (2016) · SAGE Open Medicine · doi:10.1177/2050312116682255 · Cited by 2
Dosage forms and doses of acetylsalicylic acid: significance for clinical practice
Tarlovskaya, E. I. (2018) · Kardiologiia · doi:10.18087/cardio.2466 · Cited by 2
Rivaroxaban Treatment for Left Ventricular Thrombus
Changela, J., & Anwar, M. (2019) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v72i3.2905 · Cited by 2
Steele, A. N., & Woo, Y.-P. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-20047-3_7 · Cited by 2
Aspirin Has a Neutral Effect in Preventing Future Cardiovascular Events in Vasospastic Angina
Lee, K. Y., Shin, D. I., Her, S., Han, S. H., Ahn, Y., Kim, D., Choi, D., Kwon, H. M., Gwon, H., Rha, S., et al. (2019) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2019.1.e4 · Cited by 2
A retrospective study of antithrombotic therapy use in an outpatient haemodialysis unit
Dizon, K., Ng, P., & Battistella, M. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13467 · Cited by 2
Renal function in patients receiving long-term warfarin therapy: A five-year prospective follow-up
Zemlyanskaya, O. A., Станиславовна, К. Е., Dobrovolsky, A. B., & Панченко, Е. П. (2017) · Terapevticheskii arkhiv · doi:10.17116/terarkh201789978-86 · Cited by 2
Chabior, A., Pordzik, J., Mirowska-Guzel, D. M., & Postula, M. A. (2019) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/100391 · Cited by 2
Not quite the full story on new antiplatelets
Chua, D., & Nishi, C. (2014) · Canadian Medical Association Journal · doi:10.1503/cmaj.114-0028 · Cited by 2
Efficacy and Limitations of Warfarin and Novel Oral Anticoagulants with Atrial Fibrillation
Cairns, J. A. (2015) · Contemporary cardiology · doi:10.1007/978-3-319-16280-5_2 · Cited by 1
Stratifying Thromboembolic Risk: Why Is Your Patient on Antithrombotic Medications?
Hohlfelder, B. (2018) · Springer eBooks · doi:10.1007/978-3-319-71240-6_8 · Cited by 1
Engel-Rodriguez, A., Escabí-Mendoza, J., Molina-Lopez, V. H., Engel-Rodriguez, N., & Tirú-Vega, M. (2024) · Cureus · doi:10.7759/cureus.60026 · Cited by 1
Is There Enough Evidence for Aspirin in High-Risk Groups?
Elwood, P. C., Almonte, M., & Mustafa, M. (2012) · Current Colorectal Cancer Reports · doi:10.1007/s11888-012-0149-y · Cited by 1
Role of Antiplatelet Therapies in Preventing Atherothrombosis
Khalil, M. Z. (2013) · Journal of Hematology & Thromboembolic Diseases · doi:10.4172/2329-8790.1000108 · Cited by 1
Prescribing Anticoagulation Medication for the Elderly
Palareti, G., & Cosmi, B. (2012) · Aging Health · doi:10.2217/ahe.12.11 · Cited by 1
Lyseng-Williamson, K. A. (2012) · American Journal of Cardiovascular Drugs · doi:10.2165/11209640-000000000-00000 · Cited by 1
Camuglia, A. C., Waddell-Smith, K. E., Hammett, C. J. K., & Aylward, P. E. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.949647 · Cited by 1
Has the Antiplatelet Therapy a Role in the Prevention of Sudden Cardiac Death?
García-Rubira, J. C. (2014) · Cardiovascular Pharmacology Open Access · doi:10.4172/2329-6607.1000125 · Cited by 1
Rivera, C. M., Copeland, L. A., McNeal, C. J., Mortensen, E. M., Pugh, M. J., & MacCarthy, D. (2015) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000560 · Cited by 1
Vetter, T. R., & Cheng, D. (2013) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3182982c90 · Cited by 1
Gődény, S., & Csenteri, O. K. (2015) · Orvosi Hetilap · doi:10.1556/650.2015.30254 · Cited by 1
Cardiovascular Health Disparities in Underserved Populations
Mouton, C., Hayden, M., & Southerland, J. (2019) · Physician Assistant Clinics · doi:10.1016/j.cpha.2018.08.010 · Cited by 1
Bleeding and haemostasis disorders
Mannucci, P. M., & Lettino, M. (2021) · doi:10.1093/med/9780198849346.003.0069 · Cited by 1
Funasaka, K., Yamada, H., Horiguchi, N., Osaki, H., Yoshida, D., Terada, T., Koyama, K., Okubo, M., Tahara, T., Nagasaka, M., et al. (2022) · Medicine · doi:10.1097/md.0000000000029386 · Cited by 1
Pasqualotto, E., Gewehr, D. M., Ferreira, R. O. M., Pedrotti, M., Silva, C. H., Cruz, S. A., Limachi-Choque, J., Park, A., Coutinho, M. S. S. D. A., & Kubrusly, L. F. (2024) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20230738 · Cited by 1
Handheld echocardiography saves the brain: A serendipitously found left ventricular thrombus
Shamoun, F., & Narichania, A. D. (2015) · Journal of Cardiovascular Echography · doi:10.4103/2211-4122.161780 · Cited by 1
Successful treatment of ball-shaped very late thrombus after myocardial infarction
Inami, T., Tsurumi, M., Seino, Y., & Shimizu, W. (2014) · BMJ Case Reports · doi:10.1136/bcr-2014-204340 · Cited by 1
Adverse cardiovascular events in acute coronary syndrome with indications for anticoagulation
Knight, S., McCubrey, R. O., Yuan, Ž., Woller, S. C., Horne, B. D., Bunch, T. J., Le, V. T., Mills, R. M., & Muhlestein, J. B. (2016) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716634563 · Cited by 1
Rodríguez‐Martín, S., García‐Lledó, A., Gil, M., Barreira‐Hernández, D., Rodríguez-Miguel, A., & de Abajo, F. J. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2019.10.008 · Cited by 1
Wein, T. H., Lindsay, M. P., Gladstone, D. J., Poppe, A. Y., Bell, A., Casaubon, L. K., Foley, N. C., Coutts, S. B., Cox, J. L., Douketis, J. D., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191599-f · Cited by 2
Carotid artery disease: Do women present differently than men?
Duncan, A. A., & Scallan, O. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822959-0.00038-9 · Cited by 1
Cardiovascular Drugs and Hemostasis
Farsad, B. F., & Salehi, H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-80915-3.00032-6 · Cited by 1
Aspirin for Primary Prevention: What’s a Clinician to Do?
Psotka, M. A., & Fleischmann, K. E. (2014) · Journal of General Internal Medicine · doi:10.1007/s11606-014-3108-2 · Cited by 1
Periprocedural antithrombotic management
Joo, J. D. (2014) · Journal of Korean Medical Association · doi:10.5124/jkma.2014.57.5.419 · Cited by 1
Aspirin, Colorectal Cancer, and Cause of Death: A Complex Landscape
Løberg, M., Holme, Ø., & Kalager, M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3751 · Cited by 1
Florian, A. R. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.05.034 · Cited by 1
Wada, S., Iwanaga, Y., Nakai, M., Nakao, Y. M., Miyamoto, Y., & Noguchi, T. (2022) · Research Square · doi:10.21203/rs.3.rs-1639986/v1 · Cited by 1
Evaluation of Patients with Suspected Cardiac Sources of Emboli
Harris, A. A., & Brown, D. (2013) · Springer eBooks · doi:10.1007/978-1-4471-4441-0_39
Bonten, T. N., Snoep, J. D., Roest, M., Rosendaal, F. R., & van der Bom, J. G. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12027
Aspirin for Prevention of Heart Disease and Stroke
Rifkin, E., & Lazris, A. (2014) · Springer eBooks · doi:10.1007/978-3-319-11544-3_13
Treatment of patient with high-risk hypertension: do we need antiplatelet therapy?
Minushkina, L. O., & Савина, Н. М. (2015) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2015-21-2-190-196
Metadata
- Authors
- Vandvik, P. O., Lincoff, A. M., Gore, J. M., Gutterman, D. D., Sonnenberg, F. A., Alonso-Coello, P., Akl, E. A., Lansberg, M. G., Guyatt, G. H., & Spencer, F. A.
- Affiliations
- Innlandet Hospital Trust (NO)
- Cleveland Clinic (US)
- University of Massachusetts Chan Medical School (US)
- Medical College of Wisconsin (US)
- University of Medicine and Dentistry of New Jersey (US)
- University at Buffalo, State University of New York (US)
- Stanford Medicine (US)
- McMaster University (CA)
- Corresponding author
- Spencer, Frederick A.
- ORCID
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 141
- Issue
- 2
- Pages
- e637S-e668S
- ISSN
- 0012-3692 (ISSN-L)
- PMC
- PMC3278064
- OpenAlex
- W2116051185
- Cited by
- 476
- References
- 118
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 11 · 2023: 6 · 2022: 23 · 2021: 19 · 2020: 32 · 2019: 36 · 2018: 29 · 2017: 44 · 2016: 46 · 2015: 59 · 2014: 58 · 2013: 64 · 2012: 37
- FWCI
- 44.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- CHEST Journal (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Sanofi
- National Heart, Lung, and Blood Institute (R13HL104758)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- cardiovascular disease prevention, antithrombotic therapy, antiplatelet therapy, low-dose aspirin, clopidogrel, ticagrelor, prasugrel, dual antiplatelet therapy, single antiplatelet therapy, acute coronary syndrome, percutaneous coronary intervention, coronary artery disease, drug-eluting stents, bare-metal stents, long-term aspirin therapy
- MeSH terms
- Aged, Cardiovascular Diseases, Combined Modality Therapy, Coronary Disease, Dose-Response Relationship, Drug, Drug Therapy, Combination, Fibrinolytic Agents, Humans, Long-Term Care, Middle Aged, Platelet Aggregation Inhibitors, Risk Factors, Societies, Medical, Thrombosis, Stents, Angioplasty, Balloon, Coronary, Myocardial Ischemia, Evidence-Based Medicine, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
